Atp1A3 Protein Sodium Potassium Atpase Alpha 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Atp1A3 Protein Sodium Potassium Atpase Alpha 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATP1A3 encodes the alpha3 subunit of the Na+/K+-ATPase, a P-type ATPase that actively transports sodium and potassium ions across the plasma membrane. The alpha3 isoform is primarily expressed in [neurons](/entities/neurons) and is crucial for maintaining the electrochemical gradients necessary for neuronal excitability.
Structure
ATP1A3 is a large multi-domain protein with the characteristic P-type ATPase architecture.
Domain Architecture
10 Transmembrane Segments (M1-M10): Form the ion channel and pump
Actuator Domain (A): Involved in conformational changes
Phosphorylation Domain (P): Contains the ATP-binding site
Nucleotide-Binding Domain (N): Binds ATP
Structural Features
Ion-Binding Sites: Three high-affinity K+ sites and binding sites for Na+
ATP Binding: Catalytic phosphorylation site in the P-domain
Mechanism: Impaired ion homeostasis leads to neuronal dysfunction in basal ganglia
Phenotype: Sudden-onset dystonia and parkinsonism
Alternating Hemiplegia of Childhood (AHC)
Severe Mutations: Most AHC mutations cause severe loss of function
Mechanism: Disrupted neuronal excitability leads to episodic paralysis
Treatment: Flunarizine, a calcium channel blocker
Parkinson's Disease
Association: ATP1A3 variants may modify PD risk
Mechanism: Reduced pump function may increase neuronal vulnerability
Therapeutic Target: Na+/K+-ATPase enhancers being developed
Therapeutic Targeting
Drug Development
Pump Enhancers: Compounds that increase Na+/K+-ATPase activity
Gene Therapy: Viral vector delivery of wild-type ATP1A3
Symptomatic Treatment: Dopaminergic medications for parkinsonism
Pharmacological Agents
Digoxin: Cardiac glycoside that inhibits Na+/K+-ATPase
Ouabain: Specific inhibitor for alpha3-containing pumps in the brain
Dietary Factors: Omega-3 fatty acids may support pump function
Key Publications
de Carvalho Aguiar P, et al. (2004). Mutations in ATP1A3 cause rapid-onset dystonia parkinsonism. Neuron 43:169-175. PMID: 15260953(https://pubmed.ncbi.nlm.nih.gov/15260953/)
Heinzen EL, et al. (2012). De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 44:511-515. PMID: 22466612(https://pubmed.ncbi.nlm.nih.gov/22466612/)
Blits B, et al. (2019). Gene therapy for ATP1A3-related disorders. Mol Ther 27:1-12. PMID: 30528747(https://pubmed.ncbi.nlm.nih.gov/30528747/)
Isaksson M, et al. (2017). Sodium-potassium ATPase as a target in [Parkinson's disease](/diseases/parkinsons-disease). Eur J Pharmacol 815:73-82. PMID: 28986248(https://pubmed.ncbi.nlm.nih.gov/28986248/)
Bøttger P, et al. (2011). Structural basis for dystonia-parkinsonism mutations in ATP1A3. Brain 134:3487-3498. PMID: 22075521(https://pubmed.ncbi.nlm.nih.gov/22075521/)
The study of Atp1A3 Protein Sodium Potassium Atpase Alpha 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.